Skip to Content

Generic Vanos Availability

Vanos is a brand name of fluocinonide topical, approved by the FDA in the following formulation(s):

VANOS (fluocinonide - cream;topical)

  • Manufacturer: MEDICIS
    Approval date: February 11, 2005
    Strength(s): 0.1% [RLD] [AB]

Has a generic version of Vanos been approved?

A generic version of Vanos has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Vanos and have been approved by the FDA:

fluocinonide cream;topical

  • Manufacturer: FOUGERA PHARMS INC
    Approval date: July 14, 2014
    Strength(s): 0.1% [AB]
  • Manufacturer: GLENMARK GENERICS
    Approval date: July 14, 2014
    Strength(s): 0.1% [AB]
  • Manufacturer: PERRIGO ISRAEL
    Approval date: January 14, 2014
    Strength(s): 0.1% [AB]
  • Manufacturer: TARO
    Approval date: July 14, 2014
    Strength(s): 0.1% [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vanos. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Compositions and methods for enhancing corticosteroid delivery
    Patent 6,765,001
    Issued: July 20, 2004
    Inventor(s): Eugene H.; Gans & Mitchell S.; Wortzman
    Assignee(s): Medicis Pharmaceutical Corporation
    The present invention comprises a composition, method of enhancing potency and method of delivering corticosteroids in a vehicle comprising at least two penetration enhancers, and solvents and emulsifiers. The propylene glycol and penetration enhancers are present in ratio to the total of the propylene glycol, penetration enhancers, and solvents and emulsifiers of at least about 0.70.
    Patent expiration dates:
    • December 21, 2021
      ✓ 
      Drug product
  • Compositions and methods for enhancing corticosteroid delivery
    Patent 7,220,424
    Issued: May 22, 2007
    Inventor(s): Gans; Eugene H. & Wortzman; Mitchell S.
    Assignee(s): Medicis Pharmaceutical Corporation
    The present invention comprises a composition, method of enhancing potency and method of delivering corticosteroids in a vehicle comprising at least two penetration enhancers, and solvents and emulsifiers. The propylene glycol and penetration enhancers are present in ratio to the total of the propylene glycol, penetration enhancers, and solvents and emulsifiers of at least about 0.70.
    Patent expiration dates:
    • January 7, 2023
      ✓ 
      Patent use: RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER
  • Compositions and methods for enhancing corticosteroid delivery
    Patent 7,794,738
    Issued: September 14, 2010
    Inventor(s): Gans; Eugene H. & Wortzman; Mitchell S.
    Assignee(s): Medicis Pharmaceutical Corporation
    The present invention comprises a composition, method of enhancing potency and method of delivering corticosteroids in a vehicle comprising at least two penetration enhancers, and solvents and emulsifiers. The propylene glycol and penetration enhancers are present in ratio to the total of the propylene glycol, penetration enhancers, and solvents and emulsifiers of at least about 0.70.
    Patent expiration dates:
    • September 11, 2022
      ✓ 
      Patent use: RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER
  • Compositions and methods for enhancing corticosteroid delivery
    Patent 8,232,264
    Issued: July 31, 2012
    Inventor(s): Gans; Eugene H. & Wortzman; Mitchell S.
    Assignee(s): Medicis Pharmaceutical Corporation
    The present invention comprises a composition, method of enhancing potency and method of delivering corticosteroids in a vehicle comprising at least two penetration enhancers, and solvents and emulsifiers. The propylene glycol and penetration enhancers are present in ratio to the total of the propylene glycol, penetration enhancers, and solvents and emulsifiers of at least about 0.70.
    Patent expiration dates:
    • March 9, 2023
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.
Hide